马来酸罗格列酮片治疗2型糖尿病临床效果观察  

Clinical therapeutic effect of rosiglitazone maleate on glycaemic,lipid metabolism and insulin resistance in type 2 diabetic mellitus patients

作　　者：班安然[1] 

机构地区：[1]北京安贞医院普内科,北京100029

出　　处：《海南医学院学报》2012年第3期327-329,共3页Journal of Hainan Medical University

基　　金：中国高校医学期刊临床专项资金项目(11221056)~~

摘　　要：目的:观察马来酸罗格列酮片治疗2型糖尿病患者的疗效及安全性。方法:将182例符合入选标准的2型糖尿病患者随机分为对照组和观察组,治疗12周后测定治疗前后患者的血脂、血糖、糖化血红蛋白及胰岛素水平,并计算胰岛素抵抗指数及胰岛素敏感指数。结果:治疗12周后,观察组患者TG、FPG、2hPG、Hb A1c、Fins、2hIns水平及HOMA-IR指数较治疗前均明显降低,HDL-C水平及ISI指数较治疗前明显升高;观察组患者的血脂、血糖、Hb A1c、胰岛素水平及相关指数与对照组比较,均有明显改善。结论:马来酸罗格列酮片具有明确的降糖效果,且治疗后未发生严重不良反应,是安全有效的抗糖尿病药物。To evaluate the mtluence ot roslgtttazone maleate on gtycaemlc ana llpla metabolism and insulin resistance in patients with type 2 diabetic mellitus. Methods：A total of 182 eligible patients with type 2 diabetic mellitus were randomly assigned to regular treatment group （group RT） and rosiglitazone maleate treatment group （group RM）. Plasma lipid level, plasma glucose and insulin levels and hemoglobin Alc level were measured, homeostasis model of assessment-insulin resistance and insulin sensitivity index were calculated and compared between the two groups before and after 12 weeks＇ treatment. Results：After 12 weeks treatment, the TG, FPG, 2 hPG, Hb Alc, Fins, 2 h Ins level as well as HOMAIR significantly decreased in the observation group, but HDLC and ISI levels increased. The RM group showed significant improvements in glycaemic and lipid metabolism and insulin resistance comparing with the control group. Conclusions：Rosiglitazone maleate shows significant hypoglycemic effects without producing severe side effects.

关 键 词：马来酸罗格列酮 2型糖尿病 胰岛素抵抗 β细胞保护作用 

分 类 号：R58[医药卫生—内分泌]